Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announces that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with a distinguished global Contract Research Organization (“CRO”). If consummated, the proposed transaction could expand Tevogen’s clinical development capabilities and could support the Company’s evolution into a revenue-generating healthcare enterprise.
Read the full article: Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization //
Source: https://www.globenewswire.com/news-release/2026/02/27/3246751/0/en/Tevogen-Signs-Letter-of-Intent-to-Evaluate-Potential-Acquisition-of-a-Contract-Research-Organization.html